1. Volume 62, Issue 6, Pages 2167-2175 (December 2002)
Randomized trial of darbepoetin alfa for treatment of renal anemia at a reduced dose frequency compared with rHuEPO in dialysis patients 
Yves Vanrenterghem, Peter Bárány, Johannes F.E. Mann, Peter G. Kerr, Janet Wilson, Nigel F. Baker, Stephen J. Gray 
Kidney International 
Volume 62, Issue 6, Pages (December 2002)
DOI: /j x
Copyright © 2002 International Society of Nephrology Terms and Conditions

2. Figure 1
Study design.
Kidney International  , DOI: ( /j x)
Copyright © 2002 International Society of Nephrology Terms and Conditions

3. Figure 2
Patients included in the analysis. *Includes all randomized patients who received at least one dose of the study drug. **Includes only patients who completed and had 6/8 hemoglobin assessments during the evaluation period; received the allocated study drug according to protocol; had no change to dialysis modality or route of study drug administration; and received no red blood cell transfusions during weeks 15–32 of study.
Kidney International  , DOI: ( /j x)
Copyright © 2002 International Society of Nephrology Terms and Conditions

4. Figure 3
Mean (± 2 SD) hemoglobin over time. Symbols are: (•) darbepoetin alfa (N = 347); (○) recombinant human erythropoietin (rHuEPO; N = 175). Whiskers denote standard deviation.
Kidney International  , DOI: ( /j x)
Copyright © 2002 International Society of Nephrology Terms and Conditions

5. Figure 4
Mean (95% CI) dose of study drug by route of administration. Symbols are: (▪) IV dosing; (□) SC dosing.
Kidney International  , DOI: ( /j x)
Copyright © 2002 International Society of Nephrology Terms and Conditions

6. Figure 5
Odds ratio (95% CI) between darbepoetin alfa and rHuEPO for adverse events occurring with a frequency of ≥10% in either treatment group.
Kidney International  , DOI: ( /j x)
Copyright © 2002 International Society of Nephrology Terms and Conditions